New Alzheimer's drug candidate passes first safety check in small trial

NCT ID NCT06285240

Completed Symptom relief Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested the safety and how the body handles a new drug called MK-1167 in 28 people with Alzheimer's who were already taking donepezil. The study was completed and focused on side effects and drug levels in the blood. It does not yet show whether MK-1167 helps with memory or thinking.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MK-1167
What this could lead to: If successful, this could point toward a new add-on treatment to ease Alzheimer's symptoms when combined with donepezil.
What could go wrong: This is a very early Phase 1 safety study with only 28 people. It does not test whether MK-1167 actually improves symptoms or slows the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER'S DISEASE

Contacts and locations

Locations

CenExel iResearch, LLC ( Site 0003)

Decatur, Georgia, 30030, United States
CenExel iResearch, LLC ( Site 0004)

Savannah, Georgia, 31405, United States
Velocity Clinical Research, Hallandale Beach ( Site 0001)

Hallandale, Florida, 33009, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.